Shaik, AlthafAlthafShaikBhagwat, Pranav UmeshPranav UmeshBhagwatPalanisamy, ParimaladeviParimaladeviPalanisamyChhabria, DimpleDimpleChhabriaDubey, PankajPankajDubeyKirubakaran, SivapriyaSivapriyaKirubakaranThiruvenkatam, VijayVijayThiruvenkatam2025-08-312025-08-312023-03-2210.1039/d3ce00056g2-s2.0-85153513250https://d8.irins.org/handle/IITG2025/26851Gefitinib (GEF) is an ATP-competitive inhibitor used in the treatment of advanced non-small cell lung cancer. However, the pharmaceutical efficacy of this drug is currently limited due to poor aqueous solubility (2.55 μg mL⁻¹). Therefore, we engineered three co-crystals of GEF with suitable coformers like cinnamic acid (CA), sorbic acid (SA) and resorcinol (RES). Solvent assisted grinding combined with slow evaporation of solvent resulted in three co-crystals. Structural elucidation of the crystals revealed that GEF formed a 1 : 1 co-crystal with CA (GCA), while it formed a 1 : 1 : 1 co-crystal hydrate with RES (GRES·H<inf>2</inf>O) and SA (GSA·H<inf>2</inf>O). Further, dissolution studies showed that there is an increase in the solubility of the cocrystal GCA. The synthesized co-crystals showed a comparable potency with respect to GEF in a cell viability assay. In addition, we quantified various intermolecular interactions in the co-crystals of GEF using Hirshfeld surface and 2D fingerprint plot analysis. The improvement in solubility along with the comparable efficacy of co-crystals cement the importance of pharmaceutical cocrystals in improving the physico-chemical properties of drug molecules.falseArticle146680332570-258122 March 20237arJournal6WOS:000968907900001